Cybin Inc. (NEO: CYBN), the biopharma company ‘focused on progressing Psychedelics to Therapeutics’ by creating safe and effective therapeutics for patients to address various mental health disorders, has received Institutional Review Board approval to launch the first-in-human Phase 1/2a clinical trial evaluating CYB003 for the treatment of major depressive disorder.
An Institutional Review Board, a constituted group under FDA regulations, is designated to review and monitor biomedical research involving human subjects, with the aim of protecting their rights and welfare. The board has the authority to approve, require modifications (for potential approval), or disapprove research, in accordance with FDA guidelines.
